These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 20855744)

  • 1. In vitro activities of several antimicrobial agents against recently isolated and genotyped Chlamydia trachomatis urogenital serovars D through K.
    Donati M; Di Francesco A; D'Antuono A; Delucca F; Shurdhi A; Moroni A; Baldelli R; Cevenini R
    Antimicrob Agents Chemother; 2010 Dec; 54(12):5379-80. PubMed ID: 20855744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro evaluation of activities of azithromycin, clarithromycin and sparfloxacin against Chlamydia trachomatis.
    Lefèvre JC; Escaffre MC; Courdil M; Lareng MB
    Pathol Biol (Paris); 1993 Apr; 41(4):313-5. PubMed ID: 8233628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of the in vitro susceptibility of clinical isolates of chlamydia trachomatis with serovar and duration of antibiotic exposure.
    Zheng H; Xue Y; Bai S; Qin X; Lu P; Yang B
    Sex Transm Dis; 2015 Mar; 42(3):115-9. PubMed ID: 25668641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro susceptibility of 7.5-kb common plasmid-free Chlamydia trachomatis strains.
    Miyashita N; Matsumoto A; Matsushima T
    Microbiol Immunol; 2000; 44(4):267-9. PubMed ID: 10832970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chlamydia trachomatis antimicrobial susceptibility in colorectal and endocervical cells.
    Foschi C; Salvo M; Cevenini R; Marangoni A
    J Antimicrob Chemother; 2018 Feb; 73(2):409-413. PubMed ID: 29077843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro susceptibility of recent clinical isolates of Chlamydia trachomatis to macrolides and tetracyclines.
    Samra Z; Rosenberg S; Soffer Y; Dan M
    Diagn Microbiol Infect Dis; 2001 Mar; 39(3):177-9. PubMed ID: 11337185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro effects of spectinomycin and ceftriaxone alone or in combination with other antibiotics against Chlamydia trachomatis.
    Shang S; Xia L; Zhong M; Zhang J; Zhao J; Gong X; Mabey D; Wang Q
    Antimicrob Agents Chemother; 2005 Apr; 49(4):1584-6. PubMed ID: 15793145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparative study of minimal inhibiting concentrations of doxycycline, ofloxacin and erythromycin against 18 recent isolates from Chlamydia trachomatis (1994-1995)].
    Bianchi A; Legouge R; Lefevre JC; Askienazy-Elbhar M; Joly-Guillou ML; Pavis A; Sednaoui P
    Pathol Biol (Paris); 1996 May; 44(5):347-50. PubMed ID: 8758473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evaluation of in vitro activity of ofloxacin against 73 strains of Chlamydia trachomatis isolated from gynecologic infections].
    Catalan F; Milovanovic A; Prouteau C; Soulignac M
    Pathol Biol (Paris); 1998 Feb; 46(2):144-6. PubMed ID: 9769927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activities of rifamycin derivatives ABI-1648 (Rifalazil, KRM-1648), ABI-1657, and ABI-1131 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae.
    Roblin PM; Reznik T; Kutlin A; Hammerschlag MR
    Antimicrob Agents Chemother; 2003 Mar; 47(3):1135-6. PubMed ID: 12604555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of a low-oxygen environment on the efficacy of antimicrobials against intracellular Chlamydia trachomatis.
    Shima K; Szaszák M; Solbach W; Gieffers J; Rupp J
    Antimicrob Agents Chemother; 2011 May; 55(5):2319-24. PubMed ID: 21321137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chlamydia trachomatis: in vitro susceptibility of genital and ocular isolates to some quinolones, amoxicillin and azithromycin.
    Børsum T; Dannevig L; Størvold G; Melby K
    Chemotherapy; 1990; 36(6):407-15. PubMed ID: 1963393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postantibiotic effect and postantibiotic sub-MIC effect of levofloxacin compared to those of ofloxacin, ciprofloxacin, erythromycin, azithromycin, and clarithromycin against 20 pneumococci.
    Spangler SK; Lin G; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1998 May; 42(5):1253-5. PubMed ID: 9593160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro evaluation of activities of azithromycin, erythromycin, and tetracycline against Chlamydia trachomatis and Chlamydia pneumoniae.
    Welsh LE; Gaydos CA; Quinn TC
    Antimicrob Agents Chemother; 1992 Feb; 36(2):291-4. PubMed ID: 1318677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of trovafloxacin against Chlamydia pneumoniae.
    Roblin PM; Kutlin A; Hammerschlag MR
    Antimicrob Agents Chemother; 1997 Sep; 41(9):2033-4. PubMed ID: 9303410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Etest to broth microdilution method for testing Streptococcus pneumoniae susceptibility to levofloxacin and three macrolides.
    Hunt Gerardo S; Citron DM; Claros MC; Goldstein EJ
    Antimicrob Agents Chemother; 1996 Oct; 40(10):2413-5. PubMed ID: 8891154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Susceptibility of twenty penicillin-susceptible and -resistant pneumococci to levofloxacin, ciprofloxacin, ofloxacin, erythromycin, azithromycin, and clarithromycin by MIC and time-kill.
    Visalli MA; Jacobs MR; Appelbaum PC
    Diagn Microbiol Infect Dis; 1997 Jul; 28(3):131-7. PubMed ID: 9294703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro analysis of the change in resistance of Chlamydia trachomatis under exposure to sub-MIC levofloxacin for a therapeutic term.
    Takahashi S; Hagiwara T; Shiga S; Takaoki Hirose T; Tsukamoto T
    Chemotherapy; 2000; 46(6):402-7. PubMed ID: 11053906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of levofloxacin against contemporary clinical isolates of Legionella pneumophila, Mycoplasma pneumoniae and Chlamydia pneumoniae from North America and Europe.
    Critchley IA; Jones ME; Heinze PD; Hubbard D; Engler HD; Evangelista AT; Thornsberry C; Karlowsky JA; Sahm DF
    Clin Microbiol Infect; 2002 Apr; 8(4):214-21. PubMed ID: 12047413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Susceptibility of Ureaplasma urealyticum to tetracycline, doxycycline, erythromycin, roxithromycin, clarithromycin, azithromycin, levofloxacin and moxifloxacin.
    Samra Z; Rosenberg S; Dan M
    J Chemother; 2011 Apr; 23(2):77-9. PubMed ID: 21571622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.